A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

<p><b>Background:</b> Src is involved in cancer invasion and metastasis. AZD0424, an oral inhibitor of Src and ABL1, has shown evidence of anti-tumour activity in pre-clinical studies. </p><p><b>Methods:</b> A phase Ia, dose escalation study was performed...

Full description

Bibliographic Details
Main Authors: Woodcock, V, Clive, S, Wilson, R, Coyle, V, Stratford, M, Folkes, L, Eastell, R, Barton, C, Jones, P, Kazmi-Stokes, S, Turner, H, Halford, S, Harris, A, Middleton, M
Format: Journal article
Published: Cancer Research UK 2018

Similar Items